Shares of Nivalis Therapeutics, Inc. (NASDAQ:ALPN) have been assigned a consensus rating of “Hold” from the ten brokerages that are currently covering the firm, MarketBeat reports. Two research analysts have rated the stock with a sell recommendation, four have given a hold recommendation, three have assigned a buy recommendation and one has issued a strong buy recommendation on the company. The average 12 month target price among analysts that have issued a report on the stock in the last year is $7.21.

ALPN has been the topic of several research analyst reports. Zacks Investment Research upgraded shares of Nivalis Therapeutics from a “hold” rating to a “strong-buy” rating and set a $2.75 price target on the stock in a research report on Friday, July 14th. Cowen and Company reiterated a “hold” rating on shares of Nivalis Therapeutics in a research report on Wednesday, April 19th. ValuEngine cut shares of Nivalis Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Friday, June 2nd. Finally, Ladenburg Thalmann Financial Services initiated coverage on shares of Nivalis Therapeutics in a research report on Thursday, July 27th. They set a “buy” rating and a $17.00 price target on the stock.

ILLEGAL ACTIVITY NOTICE: This news story was reported by American Banking News and is owned by of American Banking News. If you are viewing this news story on another domain, it was copied illegally and republished in violation of international copyright and trademark legislation. The legal version of this news story can be read at https://www.americanbankingnews.com/2017/08/08/nivalis-therapeutics-inc-nasdaqalpn-receives-consensus-rating-of-hold-from-brokerages.html.

In other Nivalis Therapeutics news, insider Value Fund L. P. Biotechnology acquired 17,806 shares of the business’s stock in a transaction on Tuesday, June 20th. The shares were acquired at an average price of $2.25 per share, for a total transaction of $40,063.50. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, major shareholder Bvf Partners L. P/Il acquired 35,750 shares of the business’s stock in a transaction on Monday, June 5th. The stock was acquired at an average price of $2.29 per share, for a total transaction of $81,867.50. The disclosure for this purchase can be found here. In the last 90 days, insiders acquired 397,998 shares of company stock worth $913,454. Corporate insiders own 3.00% of the company’s stock.

Shares of Nivalis Therapeutics (NASDAQ ALPN) traded down 0.21% on Tuesday, hitting $9.48. 75,265 shares of the stock were exchanged. The stock’s market cap is $12.70 million. Nivalis Therapeutics has a 52-week low of $8.00 and a 52-week high of $37.40. The company’s 50 day moving average is $9.29 and its 200-day moving average is $9.80.

About Nivalis Therapeutics

Nivalis Therapeutics, Inc is a pharmaceutical company. The Company focuses on the discovery and development of product candidates for patients with cystic fibrosis (CF). Its drug candidate portfolio consists of multiple compounds, which are designed for oral, intravenous (IV) or inhaled administration.

Analyst Recommendations for Nivalis Therapeutics (NASDAQ:ALPN)

Receive News & Ratings for Nivalis Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nivalis Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.